3 top ASX growth shares analysts rate as buys

These ASX growth shares have been named as buys…

| More on:
Person pointing finger on on an increasing graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for growth shares to buy? Listed below are three that are rated as buys by analysts.

Here's why they could be top options for investors:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX growth share to look at is Aristocrat Leisure. It is one of the world's leading gaming technology companies with a portfolio of world class pokie machines and a growing digital business. The latter has become a significant contributor to its earnings in recent years thanks to the increasing popularity of games such as Raid. And while Aristocrat missed out on acquiring London-listed leading global online gambling software and content supplier Playtech, it still has its eyes set firmly on the real money gaming market. This could be a significant growth driver in the coming years.

Morgans is positive on the company and has an add rating and $43.00 price target on its shares.

Life360 Inc (ASX: 360)

Another ASX growth share that could be a buy is Life360. It is the growing technology company behind the eponymous Life360 mobile app. This highly popular app offers families useful features such as communications, driver safety, and location sharing. At the last count, the company had over 40 million active users. This is underpinning significant recurring revenue and opening up huge cross selling opportunities.

Bell Potter is a big fan of Life360 and has a buy rating and $8.23 price target on its shares.

ResMed Inc. (ASX: RMD)

Finally, ResMed could be a growth share to buy. It is a sleep treatment-focused medical device company that has been tipped to grow strongly over the long term. This is thanks to its industry-leading products and massive market opportunity. Management estimates that there are 1 billion people impacted by sleep apnoea worldwide, with only ~20% of these sufferers diagnosed.

Goldman Sachs is bullish on ResMed and has a buy rating and $36.80 price target on its shares.

Motley Fool contributor James Mickleboro has positions in Life360, Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Inc. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 incredible ASX growth stocks to buy for 2026

These growth stocks could be well-positioned for the long-term.

Read more »